MRI agents jockey for market position (pending)

Article

With Food and Drug Administration approval pending for two newMRI contrast agents, manufacturers are jockeying for legal footholdsin this potentially explosive market. Bristol-Myers Squibb (BMS) has already swapped marketing rightswith Schering AG to

With Food and Drug Administration approval pending for two newMRI contrast agents, manufacturers are jockeying for legal footholdsin this potentially explosive market.

Bristol-Myers Squibb (BMS) has already swapped marketing rightswith Schering AG to clear the way for Prohance, an experimentalnonionic gadolinium-based agent. Schering holds patents on gadolinium-basedimage enhancement technology.

Under the terms of the Squibb-Schering deal, Schering receivesU.S. marketing rights to Squibb's antiarrhythmic agent Betapace,said Janet Skidmore, BMS director of international public affairs.BMS receives worldwide rights under Schering's existing patentsand patent applications relating to gadolinium-based Prohance.

The drug received a favorable review by FDA commissioners lastNovember and BMS predicts FDA approval by the end of the year.

"We're very optimistic that we'll see approval of Prohancein 1992. But the FDA operates in its own time frame, so we don'tknow exactly when the word will come down," Skidmore said.

Also racing to the FDA finish line is Omniscan, another nonionicgadolinium agent, manufactured by Nycomed and licensed by SterlingWinthrop.

A Schering AG representative has discounted rumors that theGerman pharmaceutical company filed a patent infringement suitagainst Nycomed and Sterling Winthrop over Omniscan (SCAN 5/20/92).Schering holds patents on gadolinium-based image enhancement technology.

"Schering has not filed any such suit for patent infringementagainst Nycomed," said Wendy Neininger, Schering's pressliaison in New York. "The rumor is unfounded."

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.